Xanamem
Asset
Inhibits 11beta-HSD1 to lower cortisol levels in the brain
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- HSD11B1
- 3
- Indications
- 1
- Trial
- 1
- Developer
Indications
3Alzheimer's disease
Phase 2, Active not recruiting, NCT06125951, clinicaltrials.gov, 7 Oct 2026
Dementia moderate
Phase 2, Active not recruiting, NCT06125951, clinicaltrials.gov, 7 Oct 2026
Mild dementia
Phase 2, Active not recruiting, NCT06125951, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 7 Oct 2026, 1 source